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INTRODUCTION
 Lysosomal storage disorders (LSDs) are a group 
of heterogeneous inherited metabolic disorders, 
comprising of 50 distinctive disorders.1 Various 
mechanisms including; defects in lysosomal 
exocytosis, reduced lysosomal catabolic efficacy, 
defects in lysosomal transport machinery, 
impairment in lysosomal metabolite efflux or 
dysfunction of lysosomal integral membrane 
proteins can result in multi systemic involvement. 
The natural course of most LSDs is a progressive 
one resulting in significant morbidity and reduced 
life expectancy. The severity of the disorders is 
also variable with symptoms ranging from in-
utero hydrops fetalis to subtle adult symptoms. 
The overall prevalence of LSDs has been estimated 
as 1 in 7000 to 1 in 8000 live births.2,3 However, 
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ABSTRACT
The lysosomal storage diseases are a group of rare, inherited metabolic diseases affecting about 1 in 7000 
to 8000 people. In recent years, the introduction of enzyme replacement therapy, substrate reduction 
therapy and small molecule therapy, has changed the natural course of this otherwise progressive group of 
disorders leading to severe morbidity and early mortality. These treatment options, however, are extremely 
expensive and are needed for life thus presenting an economical as well as ethical challenge to the 
affected families and the health care system of a country. This paper presents a case for the prevention of 
the lysosomal storage disorders as a model for other inherited metabolic disorders in the form of antenatal 
testing and cascade screening for couples and families at risk of having affected off-springs and compares 
it to the cost incurred on the enzyme replacement therapy in the backdrop of the health care priorities of 
Pakistan, a low middle income country. Similar economic and ethical challenges are faced by most low and 
middle income countries. The literature search was done using Pubmed and Clinical trials databases using 
key words: “Lysosomal storage disorders”, “natural course”, “ethics”, “cascade screening”, “Thalassemia” 
and “cascade screening”. A total of 225 articles in English language were scanned from 1980-2016, 80 
articles describing the natural course of LSD with and without ERT, ethical issues related to the treatment 
of LSD and strategies employed for the prevention of genetic disorders were prioritized.
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Ethical challenges in managing Lysosomal storage disorders
considerable variations are reported in various 
surveys conducted in different countries4,5 and 
data on the prevalence of LSDs in most low and 
middle income countries (LMICs) like Pakistan is 
scarce. Two hospital based studies by Afroze et al 
and Cheema et al. have reported 21 and 59 LSDs 
respectively. Afroze et al screened 426 patients for 
inherited metabolic disorders (IMDs), out of which 
85 patients were confirmed to have various IMDs. 
Among the confirmed IMDs patients, 21 patients 
were reported with LSD.6 Cheema et al. screened 239 
patients for IMDs and 180 patients were confirmed 
to have various IMDs. Among the confirmed IMDs 
patients, 59 patients with LSD7 were reported.
 The World Bank classifies 135 countries as 
LMICs among 215 countries based on the national 
gross income per capita.8 It is estimated that one 
billion of the current global population live in 
communities with a preference for consanguineous 
marriage.9 Autosomal recessive diseases are more 
common in communities with the tradition of 
consanguineous marriages. All LSDs are inherited 
as autosomal recessive (AR) disorders; except for 
Mucoploysaccaridosis Type-II, Fabry disease and 
Danon disease, which are inherited as X-linked 
recessive disorders.
 Like all other AR disorders, the prevalence of LSDs 
is expected to be high in LMICs like Pakistan due to 
high consanguinity rate of 62.7%.10 Seven LSDs have 
Food and Drug Administration (FDA) approved 
treatment and active research is underway for few 
others. However, these treatment options are very 
expensive and there is an exponential increase in 
cost, as the number to treat increases every year 
on year with improved survival. The doses needed 
to treat are weight based, therefore; inevitably 
increase as the children grow into adults. Therefore; 
rational treatment for LSDs is challenging even in 
High Income Countries (HIC), let alone in LMICs. 
The focus of this paper is to present the existing or 
emerging therapeutic options for various LSDs and 
compare the cost effectiveness of life-long treatment 
for treatable LSDs to the preventive reproductive 
options for high risk families to have children with 
LSDs in the back drop of economic conditions and 
health care priorities of a low income country like 
Pakistan. Similar ethical challenges are faced by 
most LMICs in allocating health care resources to 
treat rare diseases like LSDs. Countries like Pakistan 
and other LMICs have to decide whether they can 
even begin treatment for rare disorders like LSDs 
at all, whether a treatment programme might be 
possible if it is introduced alongside a programme 
of family cascade screening, to make recurrence less 
likely in the immediate and the extended family.
Theraputic options for lysosomal storage disorders; 
past, present and future: Gaucher disease was 
the first LSD to be described by Philippe Gauche 
in 188211, followed by Fabry disease in 1898, 
independently described by Johannes Anderson12 
and Fabry.13 Gaucher disease was the first LSD, for 
which the recombinant DNA-produced analogue 
of human β-glucocerebrosidase enzyme was 
developed and was approved by the FDA in 1991. 
Since then, impressive research has been undertaken 
to develop various therapeutic options for other 
LSDs. These include; enzyme replacement therapy 
(ERT), substrate reduction therapy (SRT), small 
molecules treatment to facilitating intracellular 
substrate transport, chemical chaperones, gene 
therapy, stem cell therapy, and others including 
adjunctive therapies.14
 ERT has been the most successful technology 
to date as a treatment for LSDs followed by small 
molecule therapy and SRT. The basic principal 
of ERT involves the intravenous administration 
of fully functional enzyme that is taken up by 
the cells and then delivered to the lysosomes, 
where the delivered enzyme compensates for the 
deficient enzyme.In SRT, small molecule drugs 
are ingested orally, which inhibit the first step in 
glycosphingolipid biosynthesis, aiming to reduce 
the rate of glycosphingolipid biosynthesis resulting 
in reduction of the catabolic effects.  Small molecule 
therapy either facilitates intracellular substrate 
transport or prohibits pathways triggering 
apoptosis.
 Between 1983 and 2013, fourteen drugs for seven 
LSDs received FDA approval. These include; ten 
ERT, three small molecule therapy and one SRT 
(14). For Gaucher disease; four ERT and one SRT 
have been approved, whereas for Pompe disease; 
two ERT and for Cystinosis; three SRT are included 
in the FDA approved drugs for LSDs. 
 Active research to develop effective 
treatment for more LSDs is underway. The 
LSDs for which clinical trials are in various 
phases include Mucopolysaccharidosis Type-
IIIA, Mucoploysaccharidosis Type-IVA, 
Mucoploysaccharidosis Type-VII, Metachromatic 
Leukodystrophy, Wolman Disease, Alpha-
mannosidosis and Niemann Pick C/D. The drugs 
being investigated in clinical trials are summarized 
in Table-I.
Cost of enzyme replacement therapy for lysosomal 
storage disorders in the back drop of Pakistan 
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economic and health care priorities: Over the last 
quarter of the century, the evolution of treatment 
of LSDs has been enormous. However, the health 
service cost incurred by ERT is daunting even in 
HICs. As Beutler commented in a paper written 
shortly after Cerezyme® received FDA approval, 
as ERT for Gaucher Disease “The high cost of 
alglucerase has created difficult problems for 
patients in developed countries and impossible 
ones in under-developed countries”.15 Children in 
the UK are relatively fortunate in that treatment 
for IMD (neurometabolic disorders, mitochondrial 
disorders and congenital disorders of glycosylation) 
is funded centrally as a ‘Highly Specialized Services’ 
(AGNSS).16
 After ERT, the natural course of the LSD is 
ameliorated, the disease progression is halted thus 
the complications of untreated disease causing 
death are modified leading to a near normal life 
expectancy. Thus, the ERT becomes a life-long 
requirement with an exponential increase in the 
cost of treatment, which increase every year as the 
children grow into adults. The estimated annual 
cost of some of the FDA approved ERT for treatable 
LSDs for a patient of 10 Kg are shown in Table-II. 
The annual ERT cost for a 10 kg patient with MPS-I 
is USD 67,600/year, at 40Kg it is USD 270,400/year 
and at 60 Kg, it is USD 405,600/year. Other costs 
include; portacath insertion for weekly or fortnightly 
ERT infusions, cost of consumables used for the 
intravenous infusions; day-care hospitalization 
cost for each infusion and travel cost to hospitals. 
There are potential infusion related adverse 
events(pyrexia, chills, hypertension,tachycardia, 
cutaneous reactions, headache, nausea, fatigue, 
malaise, joint pain, dyspnea, facial edema, dizziness 
and bronchospasm) for all seven FDA approved 
ERT products and the black box warnings (life-
threatening anaphylactic reactions) for four 
FDA approved ERT products alglucosidasealfa 
- Myozyme® and Lumizyme®, idursulfase - 
Elaprase®, laronidase -Aldurazyme®).17 Early 
infusions must be given by physicians experienced 
in dealing the ERT. The ERT for LSDs is either 
weekly or two weekly. Therefore; in developed 
countries like the UK and European countries18 
with home health care facilities, after successful 
ERT initiation in hospitals, later infusions are 
continued at home. This shift of hospital infusions 
to home infusions for ERT is even more challenging 
in most LMICs like Pakistan due to lack of home 
health care facilities capable of dealing with 
potential life-threatening adverse effects of the 
ERT. Thus, a patient will be admitted weekly or 
two weekly depending on the underlying LSD 
for which ERT has been commenced. Not only 
this, most LSDs require lifelong multi-disciplinary 
team care.A patient with MPS-I will need an 
ENT specialist, a cardiologist, a dentist, a general 
surgeon, an orthopedic surgeon, a neuro-surgeon, 
Bushra Afroze et al.
Table-I: LSDs treatment options under clinical trials.
Disease Drug Category Clinical Trial 
   Phase
Mucoploysaccharidosis-IIIA Recombinant human Heparan-N-Sulfatase ERT Phase 2
Mucopolysaccharidosis-IVA Recombinant human N-acetylgalactosamine- ERT Phase 3
    6-sulfatase (BMN 110)
Mucopolysaccharidosis-VII Recombinant human β-glucuronidase (UX003) ERT Phase 3
Metachtomatic Leukodystrophy Recombinant human Arylsulfastase A ERT Phase 1/2
Wolman Disease Sebelipase (SBC-102) ERT Phase 3
Alpha-mannosidosis Lamazyme ERT Phase 2
Niemann Pick C/D N-Acetylcysteine SRT Phase 1/2
 Migulstat SRT Phase 2
 2-hydroxy-proyl-beta-cyclodextrin SRT Phase 2
Table-II: Estimated annual treatment cost for some FDA approved ERT for LSDs.
Disease Product Dose per kg body weight Annual cost for 10 kg
Mucoploysaccharidosis-I Aldurazyme® 0.58 mg USD 67,600/-
Mucopolysaccharidosis-II Elaprase ® 0.5mg USD 173,182/-
Mucopolysaccharidosis-VI Naglazyme ® 1 mg USD 214,906/-
Gaucher Disease Cerezyme ® 60 IU USD 64,350/-
Pompe Disease Myozyme ® 20 mg USD 78,000/-
Fabry Disease Fabrazyme ® 1 mg USD 40,000/-
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an ophthalmologist, a developmental specialist, a 
pulmonologist, a psychologist, a geneticist and an 
ERT team of nurses. 
 In the ERT era, many physicians consider ERT 
as essential for all patients with Gaucher disease. 
Studies on the natural of Gaucher disease has 
shown little or no progression in patients with 
the homozygous c.1226A->G (N370S) mutation, 
variable progression in patients compound 
heterozygotes for a mild mutation such as N370S 
and a more severe mutation such as c.1448G->C 
(L444P), onset of symptoms at much later age in 
patients with homozygous N370S mutation.19-24
 These issues must be seen in the economic and 
ethical context of more prevalent diseases with 
greater population burden of disease. In over half 
of LMICs, at least 75 children out of every 1000 live 
births died before reaching their fifth birthday.25 
Pakistan’s mortality rate for children under five 
year is 81/1000 live births.26 The leading causes of 
under-five mortality being; birth asphyxia (22 %), 
sepsis (14 %), pneumonia (13 %), diarrhoea (11 
%) and prematurity (9 %).27 Annual cost incurred 
on treating a single patient with MPS-I of 10 Kg 
weight is equivalent to treating an estimated 8,894 
patients with pneumonia in hospital setting.28 As 
health care budgets are inelastic money spent in 
one segment of the health care economy must be 
taken from another segment. Thus, health setting 
priorities in LMICs like Pakistan demand justified 
allocation of the already scanty funds allocated to 
the field of health.Setting health care priorities may 
be considered political unpopular but has been 
practiced in the USA including Georgia, Hawaii, 
Minnesota and Oregon.29
Ethics of and options for prevention of lysosomal 
storage disorders through antenatal diagnosis and 
cascade screening: Most LSDs are inherited in an AR 
manner and, therefore, have a 25% risk of recurrence 
in each pregnancy for couples with a previously 
diagnosed child. Molecular characterization of 
the particular LSD in a family, allows the couples 
to choose an appropriate reproductive option 
most suitable for them including prenatal genetic 
testing followed by selective termination of the 
affected fetus or intro-vitro fertilization with pre-
implantation genetic diagnosis. Legal status for 
selective termination of pregnancy (TOP) varies 
among countries and may not be clearly defined 
in some LMICs. The law in Pakistan allows TOP 
under section 338 of the Pakistan Penal code, 
which was revised by the government of Pakistan 
in 1990. Under this clause, the conditions for legal 
abortion depend on the developmental stage of 
the fetus; whether the fetus’s organs are formed 
or not. Islamic scholars have usually considered 
the fetus’s organs to be formed by 120th day of 
gestation. Before 120 days of gestation, abortions 
are permitted to save the woman’s life or in order to 
provide “necessary treatment.” However, the term 
“necessary treatment” is not clearly defined in law 
and is open for interpretation.30 
 The estimated cost of antenatal testing for LSDs 
in Pakistan is about USD 2,500 -3,000, which spares 
a family from the emotional, social and life-long 
financial pressure to look after a child with LSD 
in a setting, where health is paid completely out 
of pocket. This cost is though beyond the reach 
for many families but is a one-time expense and 
much less than the potential life-long expense. 
If prevention of LSDs in the form of antenatal 
diagnosis followed by selective TOP in case of 
affected fetus is not practised, a family can have a 
second affected child with the ensuing implications 
for morbidity and financial burden. Contrary to 
the common belief, the option of selective TOP is 
already practised for genetic disorders in Pakistan.A 
22% voluntary TOP, based on parents’ anxiety and 
fear of having another child with agenetic disorder 
even in the absence of an antenatal diagnosis has 
been reported.31 
 Further prevention of the new patients born 
with a life-long expensive disease like LSD can 
be prevented by “Cascade Screening”. Cascade 
screening involves carrier testing for the siblings 
of the progeny and parents’ siblings for a genetic 
disease prevailing in that particular family. This is 
a proven method adopted to evaluate carrier status 
for individuals in at-risk population. This allows 
offering effective pre-marital genetic counseling, 
through which carriers make “informed decisions”to 
choose their potential spouses. Thus relatives of 
each patient get an opportunity to prevent the birth 
of other children with that disease. This method is 
a recognized way of decreasing disease burden of 
AR diseases in societies that practice endogamy. A 
similar approach has been applied in Pakistan for 
the prevention of beta-thalassemia, a common AR 
genetic disorder there.32 Though it raises ethical 
issues of “negative eugenics”, but is a pragmatic 
solution for unaffordable expensive genetic 
disorders like LSDs in the backdrop of the health 
care priorities in LMICs. In 1998, World Health 
Organization (WHO) published guidelines for 
genetic testing, according to which no compulsory 
genetic testing should be carried out.33 However 
Ethical challenges in managing Lysosomal storage disorders
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countries including Iran, Saudi Arabia, Palestine 
and Cyprus have laws in place making premarital 
screening for haemoglobinopathies mandatory for 
all couples before they are given approval to get 
married.34-38
 The WHO has recommended the implementation 
of community genetics programs in LMICs. The 
focus of these recommendations is the prevention 
of congenital disorders and genetic diseases at the 
population level, in addition to providing genetics 
services, including diagnosis and counseling, for 
individuals and families. At present,these include 
newborn screening for congenital hypothyroidism 
and phenylketonuria where immediate intervention 
can prevent neurocognitive harm and population 
screening for carrier detection for common 
recessive conditions, such as sickle cell anemia and 
alpha-thalassemia.39 There is immense potential to 
broaden the horizon of population screening for 
specific AR diseases, which are more prevalent 
in the specific communities, but, economically 
possible only if the disease prevalence for common 
genetic disorders is known in that population. The 
newborn screening for genetic disorders serves an 
important tool to provide this information.
 Structure of carrier screening programmes 
varies among different populations in several 
aspects, including whether the programmes are 
mandatory or voluntary, at which stage of carrier 
screening the education and counseling was 
provided; pre-marital, pre-pregnancy or antenatal, 
and whether screening test is offered pre-marital, 
pre-pregnancy or antenatally. In 1973, the Cypriot 
government started pre-marital carrier screening 
and counseling for thalassemia, which was actively 
supported by the Cypriot Orthodox Church. After 
this introduction, the number of affected births 
dropped from 51/1000 in 1974 to 8/1000 in 1979.37 
By the 1990s, the rate was 5/1000 births, between 
2002 and 2007, no affected births.40 The government 
of Pakistan passed the bill “Compulsory Blood Test 
of the Relatives of Thalassemia Patient Act 2014” in 
its’ National Assembly as an attempt to reduce the 
thalassemia burden in the country. The success of 
such measures in any country is affected by cultural, 
social and religious beliefs of the individuals and 
the society. The individuals’ ethical right of making 
“informed choices” cannot be denied by any law or 
any country. 
 In conclusion, IMDs are an example of the role 
in which paediatricians and obstetricians in LMICs 
can guide their governments and funding agencies 
in selecting the most altruistic health care priorities. 
Beutler commented in his paper “everyone wants to 
see the benefits of any possible treatment extended 
to the ill, the delivery of health care is unfortunately a 
“zero-sum game.” Means must be found to provide 
treatment, within reason, to patients with rare 
genetic diseases without depriving large numbers 
of deserving individuals of basic health care needs. 
The first step is recognition of the problem”.41
Grant Support & Financial Disclosures: None.
REFERENCES
1. Al-Jasmi FA, Tawfig N, Berniah A, Ali BR, Taleb M, 
Hertecant JL, et al. Prevalence and Novel Mutations of 
Lysosomal Storage Disorders in United Arab Emirates. 
JIMD Rep. 2013;10:1-9. doi: 10.1007/8904_2012_182.
2. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence 
of lysosomal storage disorders.  JAMA. 1999;281:249-254. 
3. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de 
Jong JG, van Weely S, et al. The frequency of lysosomal 
storage diseases in The Netherlands. Hum Genet. 
1999;105(1-2):151-156.
4. Applegarth DA, Toone JR, Lowry RB. Incidence of inborn 
errors of metabolism in British Columbia, 1969-1996. 
Pediatrics. 2000;105(1):e10.
5. Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H, et 
al. Prevalence of lysosomal storage diseases in Portugal. Eur 
J Hum Genet. 2004;12(2):87-92. doi: 10.1038/sj.ejhg.5201044.
6. Afroze B, Lakhani L, Naz F, Somani S, Yunus Z, Brown N. 
Challenges identified in the management of patients with 
inherited metabolic disorders – A five year experience from 
Pakistan. Egyp J Hum Med Genet. 2016;17:259-264. doi: 
10.1016/j.ejmhg.2016.03.002.
7. Cheema HA, Malik HS, Parkash A, Fayyaz Z. Spectrum 
of Inherited Metabolic Disorders in Pakistani Children 
Presenting at a Tertiary Care Centre. J Coll Physicians Surg 
Pak. 2016;26:498-502.
8. Country Income Groups (World Bank Classification) - 
ChartsBin.com chartsbin.com/view/2438. (Accessed on 
May 21, 2016).
9. Bittles AH, Black ML. Evolution in health and medicine 
Sackler colloquium: consanguinity, human evolution, and 
complex diseases. Proc Natl Acad Sci USA. 2010;107(Suppl 
1):1779-1786. doi: 10.1073/pnas.0906079106.
10. Hussain R, Bittles AH. The prevalence and demographic 
characteristics of consanguineous marriages in Pakistan. J 
Biosoc Sci. 1998;30:261-275.
11. Gaucher PCE (1882). De l’epitheliomaprimitif de la 
rate, hypertrophieidiopathique de la rate sans leucemie 
[Academic Thesis]. Paris, France.
12. Anderson W. A case of angiokeratoma. Br J Dermatol. 
1898;10:113.
13. Fabry J. Ein Beitrag zur Kenntnis der Purpura haemorrhagica 
nodularis (Purpura papulosa haemorrhagica Hebrae). Arch 
Dermatol Syph. 1898;43:187.
14. Mechler K, Mountford WK, Hoffmann GF, Ries M. Pressure 
for drug development in lysosomal storage disorders – a 
quantitative analysis thirty years beyond the US orphan 
drug act. Orphanet J Rare Dis. 2015;10:46. doi: 10.1186/
s13023-015-0262-5.
15. Beutler E.  Gaucher disease as a paradigm of current issues 
regarding single gene mutations of humans. Proc Natl Acad 
Sci USA. 1993;90:5384-5390.
Bushra Afroze et al.
Pak J Med Sci   2017   Vol. 33   No. 4      www.pjms.com.pk   1040
16. UK Funding for IEMs. http://www.webarchive.org.uk/
ukwa/target/136020276/(Accessed on December 8, 2016).
17. Ratko TA, Marbella A, Godfrey S, Aronson N. Enzyme-
replacement therapies for lysosomal storage diseases. 
Technical Brief No. 12.  Rockville (MD) Agency for 
Healthcare Research and Quality (US); 2013 Jan. Report No.: 
12(13)-EHC154-EF.
18. Scarpa M, Almássy Z, Beck M, Bodamer O, Bruce IS, 
Meirleir L, et al. Mucopolysaccharidosis type II: European 
recommendations for the diagnosis and multidisciplinary 
management of a rare disease. Orphanet J Rare Dis. 2011;6:1-18. 
doi: 10.1186/1750-1172-6-72
19. Balicki D, Beutler E. Gaucher disease. Medicine. 
1995;74:305-323.
20. Beutler E, Demina A, Laubscher K, Garver P, Gelbart T, 
Balicki D, et al. The clinical course of treated and untreated 
Gaucher disease. A study of 45 patients. Blood Cells Mol 
Dis. 1995;21:86-108. doi: 10.1006/bcmd.1995.0012.
21. Fallet S, Sibille A, Mendelson R, Shapiro D, Hermann G, 
Grabowski GA. Enzyme augmentation in moderate to life- 
threatening Gaucher disease. Pediatr Res. 1992;31:496-502. 
doi: 10.1203/00006450-199205000-00018.
22. Ida H, Rennert OM, Ito T, Maekawa K, Eto Y. Type 1 
Gaucher disease: phenotypic expression and natural history 
in Japanese patients. Blood Cells Mol Dis. 1998;24:73-81. doi: 
10.1006/bcmd.1998.0172.
23. Maaswinkel-Mooij P, Hollak C, Eysden-Plaisier M, Prins 
M, Aerts H, Poll R, The natural course of Gaucher disease 
in The Netherlands: implications for monitoring of disease 
manifestations. J Inherit Metab Dis. 2000;23:77-82. 
24. Zimran A, Kay AC, Gelbart T, Garver P, Saven A, Beutler E. 
Gaucher disease: clinical, laboratory, radiologic and genetic 
features of 53 patients. Medicine. 1992;71:337-353.
25. World Health Organization. Global Health Observatory 
Data. Child mortality indicators: latest situation and change 
over time http://www.who.int/gho/health_equity/
outcomes/under5_mortality_text/en/ (Accessed on May 
21, 2016).
26. Pakistan Demographic and Health Survey 2006-
07 https://dhsprogram.com/pubs/pdf/PB1/
Pakistan_2006-07_Briefing_Kit_all_6[PB1].pdf. (Accessed 
on November 10, 2015).
27. http://data.worldbank.org/indicator/SH.DYN.MORT 
(Accessed on November 10, 2015).
28. Sadruddin S, Shehzad S, Bari A, Khan A, Haque I, Khan A, 
et al. Household Costs for Treatment of Severe Pneumonia 
in Pakistan. Am J Trop Med Hyg. 2012;(Suppl 5):137-143. 
doi: 10.4269/ajtmh.2012.12-0242.
29. Povar GP, Blumen H, Daniel J, Daub S, Evans L, Holm RP, 
et al. Ethics in Practice: managed care and the changing 
health care environment: medicine as a profession managed 
care ethics working group statement. Ann Intern Med. 
2004;114:131-136.
30. United Nation. World abortion policies. 2011 [cited 
2015 June 2]. Available from: http://www.un.org/esa/
population/publications/2011abortion/2011wallchart.pdf.
31. Afroze B, Jehan F. Pre-natal genetic counseling in a resource 
limited country — a single center geneticist’s perspectives. J 
Pak Med Assoc. 2014;64:1008-1011.
32. Modell B, Darr A. Genetic counseling and customary 
consanguineous marriage. Nat Rev Genet. 2002;3:225-229. 
doi: 10.1038/nrg754.
33. Proposed International Guidelines on Ethical Issues in 
Medical Genetics and Genetic Services, World Health 
Organization, 1998. http://www.who.int/genomics/
publications/en/ethicalguidelines1998.pdf. (Accessed on 
December 8, 2016).
34. Al Hamdan NA, Al Mazrou YY, Al Swaidi FM, Choudhry 
AJ. Premarital screening for thalassemia and sickle cell 
disease in Saudi Arabia. Genet Med. 2007;9:372-377. 
doi: 10.1097GIM.0b013e318065a9e8.
35. Ghotbi N, Tsukatani T. Evaluation of the national health 
policy of thalassemia screening in the Islamic Republic 
of Iran. La Revue de Sante de la Mediterraneeorientale. 
2005;11: 308-318.
36. Samavat A, Modell B. Iranian national thalassemia screening 
programme. BMJ. 2004;329:1134-1137.
37. Angastiniotis MA, Hadjiminas MG. Prevention of 
thalassemia in Cyprus. Lancet. 1981;1:369-371.
38. Cowan R. Moving up the slippery slope: mandated genetic 
screening on Cyprus. Am J Med Genet C Semin Med Genet. 
2009;151C:95-103. doi: 10.1002/ajmg.c.30202.
39. Kingsmore SF, Lantos JD, Dinwiddie DL, Miller NA, Soden 
SE, Farrow EG, et al. Next-generation community genetics 
for low- and middle-income countries. Genome Med. 
2012;4:25. doi: 10.1186/gm324.
40. Bozkurt G. Results from the north Cyprus thalassemia 
prevention program. Hemoglobin. 2007;31:257-264. doi: 
10.1080/03630260701297204.
41. Beutler E. Lysosomal storage diseases: Natural history and 
ethical and economic aspects. Mol Genet Metab. 2006;88:208-
215. doi: 10.1016/j.ymgme.2006.01.010.
Author`s Contribution:
BA conceived, designed, did literature search and 
wrote the manuscript.
NB did review and intellectual input in the 
manuscript.
Ethical challenges in managing Lysosomal storage disorders
Pak J Med Sci   2017   Vol. 33   No. 4      www.pjms.com.pk   1041
